main content start
How do you like the content?
Breast Cancer 11m 14s

Oral Selective Estrogen Receptor Degraders for ESR-1 Mutant Metastatic Breast Cancer

Published 11 Jul 2022
Endocrine therapy is the mainstay in the management of patients with Hormone receptor positive (ER+ve) Metastatic Breast Cancer. Tumor progression in ER+ve MBC could be attributed to genomic alterations such as ESR mutations.
biomarkers esr1 mutation fulvestrant hormone receptor positive mbc serd

Disclaimer: The Views/Opinions expressed and/or opinions provided in Videos and other content on MedEnrich Website are those of respective speakers. They do not purport to reflect the opinion or views of Dr.Reddy’s Laboratories Limited or its affiliates (collectively Dr.Reddy’s)in any manner whatsoever and accordingly ,Dr.Reddys does not recommend , endorse or make any representation about the veracity and appropriateness of the views ,opinions/ information on MedEnrich website. Content on MedEnrich website may discuss uses and dosage for therapeutic product that may not have been approved in by the relevant regulatory agencies in your country. Dr.Reddy’s does not support , endorse or encourage any off-label use. Please refer to approved label before prescribing.

Perks of registering with us
Access to Online/Offline Events
Personalized Content
Access to all Features
Hi, can I help?
Chat SupportX
Support Team
Hello, how can I help you today?
Please select one of the below options.

Find Information

Unable to Login or Register

Want to share feedback